Meeting
2013 ASCO Annual Meeting
Phase II study of lapatinib in combination with vinorelbine, as first- or second-line therapy in women with HER2-overexpressing metastatic breast cancer.
Authors
Helen K. Chew
University of California, Davis Cancer Center, Sacramento, CA
Helen K. Chew , Lee Steven Schwartzberg , Suprith Badarinath , Peter Rubin , Grace Shumaker , James P. Daugherty , Michelle DeSilvio , Janine M. Mahoney
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - HER2/ER
Track
Breast Cancer
Sub Track
HER2+
Clinical Trial Registration Number
NCT00709618
Citation
J Clin Oncol 31, 2013 (suppl; abstr 621)
DOI
10.1200/jco.2013.31.15_suppl.621
Abstract #
621
Poster Bd #
11D
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress).
First Author: Ian E. Krop
Poster
2021 ASCO Annual Meeting
HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).
First Author: Ian E. Krop
Poster
2021 ASCO Annual Meeting
Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.
First Author: Min Yan
Poster
2017 ASCO Annual Meeting
A phase II study of eribulin mesylate in combination with trastuzumab and pertuzumab in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC).
First Author: Ines Maria Vaz Duarte Luis